Last reviewed · How we verify
XG-102
XG-102 is a small molecule that targets the [insert target here, if known].
At a glance
| Generic name | XG-102 |
|---|---|
| Sponsor | Xigen SA |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, I do not have information on the specific mechanism of action of XG-102.
Approved indications
Common side effects
Key clinical trials
- AM-111 in the Treatment of Acute Inner Ear Hearing Loss (PHASE3)
- Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment (PHASE3)
- Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain (PHASE3)
- Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation (PHASE3)
- Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss (PHASE2)
- Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XG-102 CI brief — competitive landscape report
- XG-102 updates RSS · CI watch RSS
- Xigen SA portfolio CI